AzurRx BioPharma, Inc. (AZRX)
AzurRx BioPharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Brooklyn, NY, US. The stock last traded at $3.45, up 2.07% on the session, giving a market capitalisation of $3.4M. On trailing twelve-month figures it carries a trailing P/E of -0.73, a net margin of -11728.1%. Its beta of 1.51 implies it has historically moved more than the broad market.
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
AzurRx BioPharma, Inc. is most often compared with the following Healthcare names: